Discussing a T2D Medication That Could Reduce Insulin Needs in T1D

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA Guest: David Selzer, MD New research suggests that a GLP-1 receptor agonist medication, semaglutide, which has been approved for type 2 diabetes and obesity, could also be used to treat type 1 diabetes in patients. So what are the risks for patients who have type 1 diabetes and who are obese? Joining Dr. Mary Katherine Cheeley to discuss this is Dr. David Selzer, Clinical Instructor of Medicine at NYU Grossman School of Medicine and leads the Medical Weight Loss Program at NYU Langone Medical Associates in the Florida Division.

Episode metadata supplied by the publisher feed · Published Nov 27, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Discussing a T2D Medication That Could Reduce Insulin Needs in T1D

0:00 11:30

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

This is Type 1: Real-Life Type 1 Diabetes Colleen Mitchell Type 1 Diabetes is challenging, frustrating, and life-changing. Each Tuesday, join Colleen Mitchell and Jessie Tuggey, life-long diabetics, as they talk about real life with Type 1, discussing the impact it makes on their lives without defining them. If you have type 1, know someone with type 1, or just want to learn more about this incurable condition, this podcast is for you.

Frequently Asked Questions

How long is this episode of Diabetes Discourse?

This episode is 11 minutes long.

When was this Diabetes Discourse episode published?

This episode was published on November 27, 2023.

Can I download this Diabetes Discourse episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!